https://endeavorbiomedicines.com/ 1.00 https://endeavorbiomedicines.com/media/ 0.80 https://endeavorbiomedicines.com/media/in-the-news/ 0.80 https://endeavorbiomedicines.com/media/media-contact/ 0.80 https://endeavorbiomedicines.com/join-us/ 0.80 https://endeavorbiomedicines.com/contact/ 0.80 https://endeavorbiomedicines.com/therapeutic-areas/ 0.80 https://endeavorbiomedicines.com/therapeutic-areas/fibrotic-lung-disease/ 0.80 https://endeavorbiomedicines.com/our-science/ 0.80 https://endeavorbiomedicines.com/our-science/pipeline/ 0.80 https://endeavorbiomedicines.com/our-science/env-101/ 0.80 https://endeavorbiomedicines.com/our-science/clinical-trials/ 0.80 https://endeavorbiomedicines.com/about-us/ 0.80 https://endeavorbiomedicines.com/about-us/leadership/ 0.80 https://endeavorbiomedicines.com/about-us/bod/ 0.80 https://endeavorbiomedicines.com/about-us/advisors/ 0.80 https://endeavorbiomedicines.com/about-us/investors/ 0.80 https://endeavorbiomedicines.com/our-science/publications/ 0.80 https://endeavorbiomedicines.com/legal-notices/ 0.80 https://endeavorbiomedicines.com/privacy/ 0.80 https://endeavorbiomedicines.com/ats/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-receives-priority-medicines-prime-designation-from-the-european-medicines-agency-for-taladegib-env-101-for-the-treatment-of-idiopathic-pulmonary-fibrosis/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-to-present-results-from-phase-2a-trial-of-taladegib-env-101-in-an-alert-session-at-european-respiratory-society-ers-congress-2025/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-announces-publication-of-positive-data-from-phase-2a-trial-in-the-lancet-respiratory-medicine-evaluating-taladegib-env101-in-individuals-with-idiopathic-pulmonary-fibrosis/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-appoints-enoch-kariuki-pharm-d-as-president-and-vishaal-turakhia-as-chief-financial-officer/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-successfully-completes-phase-2a-trial-of-env-101-in-patients-with-idiopathic-pulmonary-fibrosis/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-appoints-enoch-kariuki-pharm-d-to-board-of-directors/ 0.80 https://endeavorbiomedicines.com/endeavor-biomedicines-appoints-paul-frohna-m-d-ph-d-as-chief-medical-officer/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-enters-license-agreement-with-hummingbird-bioscience-for-worldwide-rights-to-hmbd-501-a-next-generation-her3-targeted-antibody-drug-conjugate-adc/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-closes-101m-series-b-financing-to-advance-clinical-stage-precision-medicine-pipeline/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-doses-first-patient-in-phase-2-clinical-trial-of-taladegib-env-101-for-idiopathic-pulmonary-fibrosis-appoints-chief-medical-officer/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-launches-with-62-million-series-a-financing-and-mission-to-reverse-the-course-of-devastating-pulmonary-disease/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-receives-orphan-drug-designation-from-the-u-s-food-and-drug-administration-and-european-commission-for-taladegib-env-101-for-the-treatment-of-idiopathic-pulmonary-fibrosis/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-presents-new-clinical-findings-from-post-hoc-analysis-of-phase-2a-clinical-trial-evaluating-env-101-in-patients-with-idiopathic-pulmonary-fibrosis/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-announces-upcoming-presentations-at-the-2025-american-thoracic-society-international-conference/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-appoints-internationally-renowned-ild-expert-lisa-lancaster-m-d-as-chief-medical-officer/ 0.64 https://endeavorbiomedicines.com/first-patient-dosed-in-endeavor-biomedicines-phase-2b-whistle-pf-trial-evaluating-env-101-for-the-treatment-of-idiopathic-pulmonary-fibrosis/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-appoints-bill-bradford-m-d-ph-d-to-board-of-directors/ 0.64 https://endeavorbiomedicines.com/new-phase-2a-clinical-trial-results-demonstrate-endeavor-biomedicines-env-101-improved-lung-function-and-reversed-key-measures-of-lung-fibrosis-in-patients-with-idiopathic-pulmonary-fibrosis/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-to-present-new-data-from-phase-2a-clinical-trial-of-env-101-at-american-thoracic-society-2024-international-conference/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-raises-132-5-million-oversubscribed-series-c-financing-to-advance-pipeline-of-transformational-medicines/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-announces-appointment-of-chris-krueger-j-d-as-chief-operating-officer/ 0.64 https://endeavorbiomedicines.com/endeavor-biomedicines-completes-enrollment-in-phase-2a-clinical-trial-of-env-101-taladegib-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf/ 0.64